Gossamer Bio Inc. (GOSS) Misses Q1 EPS by 25c

Gossamer Bio Inc. (NASDAQ: GOSS) reported Q1 EPS of ($0.90), $0.25 worse than the analyst estimate of ($0.65).

“In the three months since our initial public offering, we have made significant further advancements in building an operationally efficient biotechnology company with a diversified portfolio of potential new therapies in multiple disease areas with high unmet need,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “This is an exciting and productive time for Gossamer, and we look forward to numerous data readouts in 2020. Our team’s track record of success and our strong balance sheet positions us well to realize our goal of becoming an industry leader in immunology, inflammation and oncology.”

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Rocket Companies adds Sarah Watterson to its board of directors
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c